Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions

Rivaroxaban has been investigated in the EINSTEIN‐Jr program for the treatment of acute venous thromboembolism (VTE) in children aged 0 to 18 years and in the UNIVERSE program for thromboprophylaxis in children aged 2 to 8 years with congenital heart disease after Fontan‐procedure. Physiologically‐b...

Descripción completa

Detalles Bibliográficos
Autores principales: Willmann, Stefan, Coboeken, Katrin, Zhang, Yang, Mayer, Hannah, Ince, Ibrahim, Mesic, Emir, Thelen, Kirstin, Kubitza, Dagmar, Lensing, Anthonie W. A., Yang, Haitao, Zhu, Peijuan, Mück, Wolfgang, Drenth, Henk‐Jan, Lippert, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520753/
https://www.ncbi.nlm.nih.gov/pubmed/34292671
http://dx.doi.org/10.1002/psp4.12688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520753/
https://www.ncbi.nlm.nih.gov/pubmed/34292671
http://dx.doi.org/10.1002/psp4.12688

Ejemplares similares